RAPT Therapeutics, Inc. (RAPT)
Mar 3, 2026 - RAPT was delisted (reason: acquired by GSK)
58.02
0.00 (0.00%)
Inactive · Last trade price on Mar 2, 2026
RAPT Therapeutics Stock Forecast
Stock Price Forecast
The 9 analysts with 12-month price forecasts for RAPT Therapeutics stock had an average target of 56.22, with a low estimate of 9.00 and a high estimate of 80.
Price Target: $56.22 (-3.10%)
Analyst Consensus: Buy
* Price targets were last updated on Jan 21, 2026.
Analyst Ratings
The average analyst rating for RAPT Therapeutics stock from 10 stock analysts was "Buy". This means that analysts believed this stock was likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 2 | 2 | 2 |
| Buy | 4 | 4 | 4 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 7 | 7 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 10 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barclays | Barclays | Buy → Hold Downgrades $58 | Buy → Hold | Downgrades | $58 | -0.03% | Jan 21, 2026 |
| Leerink Partners | Leerink Partners | Buy → Hold Downgrades $58 | Buy → Hold | Downgrades | $58 | -0.03% | Jan 21, 2026 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $58 | Buy → Hold | Downgrades | $58 | -0.03% | Jan 20, 2026 |
| TD Cowen | TD Cowen | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Jan 20, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $58 | Strong Buy → Hold | Downgrades | $58 | -0.03% | Jan 20, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-2.64
from -25.49
EPS Next Year
-3.31
from -2.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.00 | -1.86 | ||||
| Avg | -2.64 | -3.31 | ||||
| Low | -3.47 | -4.18 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.